Third, given the prevalent incidence of upregulated CIP2A and Akt in various cancers [24, 47], our understanding of CIP2A and lapatinib resistance may also shed light on the mechanisms of the resistance to other ErbB2-targeting drugs, such as trastuzumab. Here, ERBB2 is linked to cancer.